Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2011, Article ID 727241, 11 pages
http://dx.doi.org/10.1155/2011/727241
Review Article

Targeted Liposomal Drug Delivery to Monocytes and Macrophages

1School of Pharmacy, Royal College of Surgeons in Ireland, Dublin 2, Ireland
2Department of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland

Received 30 July 2010; Accepted 27 September 2010

Academic Editor: Juan M. Irache

Copyright © 2011 Ciara Kelly et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. S. Ravichandran and U. Lorenz, “Engulfment of apoptotic cells: signals for a good meal,” Nature Reviews Immunology, vol. 7, no. 12, pp. 964–974, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Eue, “Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: participation of activated macrophages in the antitumor mechanism,” International Journal of Cancer, vol. 92, no. 3, pp. 426–433, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Eue, R. Kumar, Z. Dong, J. J. Killion, and I. J. Fidler, “Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes,” Journal of Immunotherapy, vol. 21, no. 5, pp. 340–351, 1998. View at Google Scholar · View at Scopus
  4. J. J. Killion and I. J. Fidler, “Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators,” Pharmacology and Therapeutics, vol. 78, no. 3, pp. 141–154, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Chono, T. Tanino, T. Seki, and K. Morimoto, “Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections,” Journal of Controlled Release, vol. 127, no. 1, pp. 50–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Kole, L. Das, and P. K. Das, “Synergistic effect of interferon-γ and mannosylated liposome- incorporated doxorubicin in the therapy of experimental visceral leishmaniasis,” Journal of Infectious Diseases, vol. 180, no. 3, pp. 811–820, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. N. van Rooijen and A. Sanders, “The macrophage as target or obstacle in liposome-based targeting strategies,” International Journal of Pharmaceutics, vol. 162, no. 1-2, pp. 45–50, 1998. View at Google Scholar
  8. B. Burke, S. Sumner, N. Maitland, and C. E. Lewis, “Macrophages in gene therapy: cellular delivery vehicles and in vivo targets,” Journal of Leukocyte Biology, vol. 72, no. 3, pp. 417–428, 2002. View at Google Scholar · View at Scopus
  9. M. L. Immordino, F. Dosio, and L. Cattel, “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential,” International Jurnal of Nanomedicine, vol. 1, no. 3, pp. 297–315, 2006. View at Google Scholar · View at Scopus
  10. C. Varol, S. Yona, and S. Jung, “Origins and tissue-context-dependent fates of blood monocytes,” Immunology and Cell Biology, vol. 87, no. 1, pp. 30–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. S. Robbins and F. K. Swirski, “The multiple roles of monocyte subsets in steady state and inflammation,” Cellular and Molecular Life Sciences, vol. 67, no. 16, pp. 2685–2693, 2010. View at Publisher · View at Google Scholar
  12. M. Naito, “Macrophage differentiation and function in health and disease,” Pathology International, vol. 58, no. 3, pp. 143–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Benoit, B. Desnues, and J.-L. Mege, “Macrophage polarization in bacterial infections,” Journal of Immunology, vol. 181, no. 6, pp. 3733–3739, 2008. View at Google Scholar · View at Scopus
  14. A. Mantovani, A. Sica, and M. Locati, “Macrophage polarization comes of age,” Immunity, vol. 23, no. 4, pp. 344–346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. O. Martinez, A. Sica, A. Mantovani, and M. Locati, “Macrophage activation and polarization,” Frontiers in Bioscience, vol. 13, no. 2, pp. 453–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Makkouk and A. M. Abdelnoor, “The potential use of toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents,” Immunopharmacology and Immunotoxicology, vol. 31, no. 3, pp. 331–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Christensen, E. M. Agger, L. V. Andreasen, D. Kirby, P. Andersen, and Y. Perrie, “Liposome-based cationic adjuvant formulations (CAF): past, present, and future,” Journal of Liposome Research, vol. 19, no. 1, pp. 2–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Diwan, P. Elamanchili, H. Lane, A. Gainer, and J. Samuel, “Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses,” Journal of Drug Targeting, vol. 11, no. 8-10, pp. 495–507, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. B. Coffelt, R. Hughes, and C. E. Lewis, “Tumor-associated macrophages: effectors of angiogenesis and tumor progression,” Biochimica et Biophysica Acta, vol. 1796, no. 1, pp. 11–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. H.-P. Gerber, E. Olazoglu, and I. S. Grewal, “Targeting inflammatory cells to improve anti-VEGF therapies in oncology,” Recent Results in Cancer Research, vol. 180, pp. 185–200, 2010. View at Publisher · View at Google Scholar
  21. C. L. Van Broekhoven, C. R. Parish, C. Demangel, W. J. Britton, and J. G. Altin, “Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy,” Cancer Research, vol. 64, no. 12, pp. 4357–4365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Chono, Y. Tauchi, Y. Deguchi, and K. Morimoto, “Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice,” Journal of Drug Targeting, vol. 13, no. 4, pp. 267–276, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. A. M. Gibbons, N. G. McElvaney, C. C. Taggart, and S.-A. Cryan, “Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation,” Journal of Microencapsulation, vol. 26, no. 6, pp. 513–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Epstein-Barash, D. Gutman, E. Markovsky et al., “Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death,” Journal of Controlled Release, vol. 146, no. 2, pp. 182–195, 2010. View at Publisher · View at Google Scholar
  25. S. P. Vyas, M. E. Kannan, S. Jain, V. Mishra, and P. Singh, “Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages,” International Journal of Pharmaceutics, vol. 269, no. 1, pp. 37–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Oussoren, M. Magnani, A. Fraternale et al., “Liposomes as carriers of the antiretroviral agent dideoxycytidine-5'-triphosphate,” International Journal of Pharmaceutics, vol. 180, no. 2, pp. 261–270, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. I. I. Salem and N. Düzgünes, “Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages,” International Journal of Pharmaceutics, vol. 250, no. 2, pp. 403–414, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Nardin, M.-L. Lefebvre, K. Labroquère, O. Faure, and J.-P. Abastado, “Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma,” Current Cancer Drug Targets, vol. 6, no. 2, pp. 123–133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Jain, V. Mishra, P. Singh, P. K. Dubey, D. K. Saraf, and S. P. Vyas, “RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting,” International Journal of Pharmaceutics, vol. 261, no. 1-2, pp. 43–55, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. P. I. Homem de Bittencourt Jr., D. J. Lagranha, A. Maslinkiewicz et al., “LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions,” Atherosclerosis, vol. 193, no. 2, pp. 245–258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. G. A. Koning, H. W. M. Morselt, A. Gorter et al., “Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison,” Pharmaceutical Research, vol. 20, no. 8, pp. 1249–1257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. G. A. Koning, J. A. A. M. Kamps, and G. L. Scherphof, “Interference of macrophages with immunotargeting of liposomes,” Journal of Liposome Research, vol. 12, no. 1-2, pp. 107–119, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Wijagkanalan, Y. Higuchi, S. Kawakami, M. Teshima, H. Sasaki, and M. Hashida, “Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model,” Molecular Pharmacology, vol. 74, no. 5, pp. 1183–1192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Espuelas, C. Thumann, B. Heurtault, F. Schuber, and B. Frisch, “Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes,” Bioconjugate Chemistry, vol. 19, no. 12, pp. 2385–2393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Ishii and N. Kojima, “Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization,” Glycoconjugate Journal, vol. 27, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Matsui, Y. Shimizu, Y. Kodera, E. Kondo, Y. Ikehara, and H. Nakanishi, “Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer,” Cancer Science, vol. 101, no. 7, pp. 1670–1677, 2010. View at Publisher · View at Google Scholar
  37. F. Ahsan, I. P. Rivas, M. A. Khan, and A. I. Torres Suárez, “Targeting to macrophages: role of physicochemical properties of particulate carriers—Liposomes and microspheres—on the phagocytosis by macrophages,” Journal of Controlled Release, vol. 79, no. 1–3, pp. 29–40, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Takano, Y. Aramaki, and S. Tsuchiya, “Physicochemical properties of liposomes affecting apoptosis induced by cationic liposomes in macrophages,” Pharmaceutical Research, vol. 20, no. 7, pp. 962–968, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Chono, T. Tanino, T. Seki, and K. Morimoto, “Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes,” Journal of Drug Targeting, vol. 14, no. 8, pp. 557–566, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Chono, Y. Tauchi, and K. Morimoto, “Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice,” Drug Development and Industrial Pharmacy, vol. 32, no. 1, pp. 125–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Chono, T. Tanino, T. Seki, and K. Morimoto, “Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification,” Journal of Pharmacy and Pharmacology, vol. 59, no. 1, pp. 75–80, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Yan, G. L. Scherphof, and J. A. A. M. Kamps, “Liposome opsonization,” Journal of Liposome Research, vol. 15, no. 1-2, pp. 109–139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. I. S. Zuhorn, J. B. F. N. Engberts, and D. Hoekstra, “Gene delivery by cationic lipid vectors: overcoming cellular barriers,” European Biophysics Journal, vol. 36, no. 4-5, pp. 349–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. C. M. Wiethoff, J. G. Smith, G. S. Koe, and C. R. Middaugh, “The potential role of proteoglycans in cationic lipid-mediated gene delivery: studies of the interaction of cationic lipid-DNA complexes with model glycosaminoglycans,” The Journal of Biological Chemistry, vol. 276, no. 35, pp. 32806–32813, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan, “Toxicity of cationic lipids and cationic polymers in gene delivery,” Journal of Controlled Release, vol. 114, no. 1, pp. 100–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Iwaoka, T. Nakamura, S. Takano, S. Tsuchiya, and Y. Aramaki, “Cationic liposomes induce apoptosis through p38 MAP kinase-caspase-8-Bid pathway in macrophage-like RAW264.7 cells,” Journal of Leukocyte Biology, vol. 79, no. 1, pp. 184–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Aramaki, S. Takano, and S. Tsuchiya, “Cationic liposomes induce macrophage apoptosis through mitochondrial pathway,” Archives of Biochemistry and Biophysics, vol. 392, no. 2, pp. 245–250, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Arisaka et al., “Involvement of protein kinase Cdelta in induction of apoptosis by cationic liposomes in macrophage-like RAW264.7 cells,” FEBS Letters, vol. 584, no. 5, pp. 1016–1020, 2010. View at Google Scholar
  49. I. J. Fidler, A. Raz, and W. E. Fogler, “Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages,” Cancer Research, vol. 40, no. 12, pp. 4460–4466, 1980. View at Google Scholar · View at Scopus
  50. A. Gibbons et al., “Liposome Encapsulation Influences Pharmacokinetics and Activity of recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) after Local Delivery to the Lungs: an In Vitro and In Vivo Assessment,” in Proceedings of the American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Atlanta, Ga, USA, 2008.
  51. I. M. Hafez and P. R. Cullis, “Roles of lipid polymorphism in intracellular delivery,” Advanced Drug Delivery Reviews, vol. 47, no. 2-3, pp. 139–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. G. L. Scherphof and J. A. A. M. Kamps, “Receptor versus non-receptor mediated clearance of liposomes,” Advanced Drug Delivery Reviews, vol. 32, no. 1-2, pp. 81–97, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. S. M. Moghimi and A. C. Hunter, “Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups,” Pharmaceutical Research, vol. 18, no. 1, pp. 1–8, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Foged, C. Arigita, A. Sundblad, W. Jiskoot, G. Storm, and S. Frokjaer, “Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition,” Vaccine, vol. 22, no. 15-16, pp. 1903–1913, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Sun, M. Zhong, X. Shi, and Z. Li, “Anionic LPD complexes for gene delivery to macrophage: preparation, characterization and transfection in vitro,” Journal of Drug Targeting, vol. 16, no. 9, pp. 668–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Andreakos, U. Rauchhaus, A. Stavropoulos et al., “Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis,” Arthritis and Rheumatism, vol. 60, no. 4, pp. 994–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. R. L. Juliano, R. Alam, V. Dixit, and H. M. Kang, “Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents,” Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, vol. 1, no. 3, pp. 324–335, 2009. View at Publisher · View at Google Scholar
  58. E. Karathanasis, C. M. Geigerman, C. A. Parkos, L. Chan, R. V. Bellamkonda, and D. L. Jaye, “Selective targeting of nanocarriers to neutrophils and monocytes,” Annals of Biomedical Engineering, vol. 37, no. 10, pp. 1984–1992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Mazzucchelli, J. B. Burritt, A. J. Jesaitis et al., “Cell-specific peptide binding by human neutrophils,” Blood, vol. 93, no. 5, pp. 1738–1748, 1999. View at Google Scholar · View at Scopus
  60. J. Qin, D. Chen, H. Hu, M. Qiao, X. Zhao, and B. Chen, “Body distributioin of RGD-mediated liposome in brain-targeting drug delivery,” Yakugaku Zasshi, vol. 127, no. 9, pp. 1497–1501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Qin, D. Chen, H. Hu, Q. Cui, M. Qiao, and B. Chen, “Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain,” Chemical and Pharmaceutical Bulletin, vol. 55, no. 8, pp. 1192–1197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. T. E. Wileman, M. R. Lennartz, and P. D. Stahl, “Identification of the macrophage mannose receptor as a 175-kDa membrane protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 8, pp. 2501–2505, 1986. View at Google Scholar · View at Scopus
  63. E. P. McGreal, L. Martinez-Pomares, and S. Gordon, “Divergent roles for C-type lectins expressed by cells of the innate immune system,” Molecular Immunology, vol. 41, no. 11, pp. 1109–1121, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. V. L. Shepherd, Y. C. Lee, P. H. Schlesinger, and P. D. Stahl, “L-Fucose-terminated glycoconjugates are recognized by pinocytosis receptors on macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 2, pp. 1019–1022, 1981. View at Google Scholar · View at Scopus
  65. P. D. Stahl, J. S. Rodman, M. J. Miller, and P. H. Schlesinger, “Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 3, pp. 1399–1403, 1978. View at Google Scholar · View at Scopus
  66. J. M. Irache, H. H. Salman, C. Gamazo, and S. Espuelas, “Mannose-targeted systems for the delivery of therapeutics,” Expert Opinion on Drug Delivery, vol. 5, no. 6, pp. 703–724, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. U. Gazi and L. Martinez-Pomares, “Influence of the mannose receptor in host immune responses,” Immunobiology, vol. 214, no. 7, pp. 554–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. E. J. McKenzie, P. R. Taylor, R. J. Stillion et al., “Mannose receptor expression and function define a new population of murine dendritic cells,” Journal of Immunology, vol. 178, no. 8, pp. 4975–4983, 2007. View at Google Scholar · View at Scopus
  69. S. Chono, K. Kaneko, E. Yamamoto, K. Togami, and K. Morimoto, “Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages,” Drug Development and Industrial Pharmacy, vol. 36, no. 1, pp. 102–107, 2010. View at Publisher · View at Google Scholar
  70. A. Engel, S. K. Chatterjee, A. Al-arifi, D. Riemann, J. Langner, and P. Nuhn, “Influence of spacer length on interaction of mannosylated liposomes with human phagocytic cells,” Pharmaceutical Research, vol. 20, no. 1, pp. 51–57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Takagi, M. Numazaki, T. Kajiwara et al., “Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages,” Glycobiology, vol. 19, no. 3, pp. 258–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. W. Wijagkanalan, S. Kawakami, M. Takenaga, R. Igarashi, F. Yamashita, and M. Hashida, “Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats,” Journal of Controlled Release, vol. 125, no. 2, pp. 121–130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Un, S. Kawakami, R. Suzuki, K. Maruyama, F. Yamashita, and M. Hashida, “Enhanced transfection efficiency into macrophages and dendritic cells by a combination method using mannosylated lipoplexes and bubble liposomes with ultrasound exposure,” Human Gene Therapy, vol. 21, no. 1, pp. 65–74, 2010. View at Google Scholar
  74. S. Kawakami, A. Sato, M. Nishikawa, F. Yamashita, and M. Hashida, “Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes,” Gene Therapy, vol. 7, no. 4, pp. 292–299, 2000. View at Google Scholar · View at Scopus
  75. S. Kawakami, J. Wong, A. Sato, Y. Hattori, F. Yamashita, and M. Hashida, “Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice,” Biochimica et Biophysica Acta, vol. 1524, no. 2-3, pp. 258–265, 2000. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Chono, K. Kaneko, E. Yamamoto, K. Togami, and K. Morimoto, “Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages,” Drug Development and Industrial Pharmacy, vol. 36, no. 1, pp. 102–107, 2010. View at Publisher · View at Google Scholar
  77. K. Nakamura, Y. Kuramoto, H. Mukai, S. Kawakami, Y. Higuchi, and M. Hashida, “Enhanced gene transfection in macrophages by histidine-conjugated mannosylated cationic liposomes,” Biological and Pharmaceutical Bulletin, vol. 32, no. 9, pp. 1628–1631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Kelly et al., “Mannosylated liposomes for targeted delivery of siRNA to alveolar macrophages,” in Proceedings of the 7th British Society for Gene Therapy Annual Conference, London, UK, 2010.
  79. Y. Kuramoto, S. Kawakami, S. Zhou, K. Fukuda, F. Yamashita, and M. Hashida, “Use of mannosylated cationic liposomes/immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice,” Journal of Gene Medicine, vol. 10, no. 4, pp. 392–399, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Dornand, A. Gross, V. Lafont, J. Liautard, J. Oliaro, and J.-P. Liautard, “The innate immune response against Brucella in humans,” Veterinary Microbiology, vol. 90, no. 1–4, pp. 383–394, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. C. A. Carter and L. S. Ehrlich, “Cell biology of HIV-1 infection of macrophages,” Annual Review of Microbiology, vol. 62, pp. 425–443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Cassol, M. Alfano, P. Biswas, and G. Poli, “Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence,” Journal of Leukocyte Biology, vol. 80, no. 5, pp. 1018–1030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Pieters and J. Gatfield, “Hijacking the host: survival of pathogenic mycobacteria inside macrophages,” Trends in Microbiology, vol. 10, no. 3, pp. 142–146, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Gunaseelan, K. Gunaseelan, M. Deshmukh, X. Zhang, and P. J. Sinko, “Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs,” Advanced Drug Delivery Reviews, vol. 62, no. 4-5, pp. 518–531, 2010. View at Publisher · View at Google Scholar
  85. E. Ojewole, I. Mackraj, P. Naidoo, and T. Govender, “Exploring the use of novel drug delivery systems for antiretroviral drugs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 3, pp. 697–710, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Bestman-Smith, P. Gourde, A. Désormeaux, M. J. Tremblay, and M. G. Bergeron, “Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1,” Biochimica et Biophysica Acta, vol. 1468, no. 1-2, pp. 161–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  87. A. K. Agrawal and C. M. Gupta, “Tuftsin-bearing liposomes in treatment of macrophage-based infections,” Advanced Drug Delivery Reviews, vol. 41, no. 2, pp. 135–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Garg and N. K. Jain, “Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes,” Journal of Drug Targeting, vol. 14, no. 1, pp. 1–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Garg, A. Asthana, H. B. Agashe, G. P. Agrawal, and N. K. Jain, “Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics,” Journal of Pharmacy and Pharmacology, vol. 58, no. 5, pp. 605–616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. T. Liu, N. Van Rooijen, and D. J. Tracey, “Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury,” Pain, vol. 86, no. 1-2, pp. 25–32, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. E. Haber, H. D. Danenberg, N. Koroukhov, R. Ron-El, G. Golomb, and M. Schachter, “Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model,” Human Reproduction, vol. 24, no. 2, pp. 398–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Hiraoka, M. Zenmyo, K. Watari et al., “Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages,” Cancer Science, vol. 99, no. 8, pp. 1595–1602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. P. J. Richards, B. D. Williams, and A. S. Williams, “Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate,” Rheumatology, vol. 40, no. 9, pp. 978–987, 2001. View at Google Scholar · View at Scopus
  94. H. D. Danenberg, G. Golomb, A. Groothuis et al., “Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits,” Circulation, vol. 108, no. 22, pp. 2798–2804, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. M. V. Calin, I. Manduteanu, E. Dragomir et al., “Effect of depletion of monocytes/macrophages on early aortic valve lesion in experimental hyperlipidemia,” Cell and Tissue Research, vol. 336, no. 2, pp. 237–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Van Rooijen, “Manipulation of Kupffer cells by liposome encapsulated clodronate and propamidine—synergistic and antagonistic effects of liposomal phospholipids and drugs,” International Journal of Pharmaceutics, vol. 162, no. 1-2, pp. 51–58, 1998. View at Google Scholar
  97. E. Galkina and K. Ley, “Immune and inflammatory mechanisms of atherosclerosis,” Annual Review of Immunology, vol. 27, pp. 165–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. K. J. Woollard and F. Geissmann, “Monocytes in atherosclerosis: subsets and functions,” Nature Reviews Cardiology, vol. 7, no. 2, pp. 77–86, 2010. View at Publisher · View at Google Scholar
  99. A. Demers, N. McNicoll, M. Febbraio et al., “Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study,” Biochemical Journal, vol. 382, no. 2, pp. 417–424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. K. C. Briley-Saebo, W. J. M. Mulder, V. Mani et al., “Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes,” Journal of Magnetic Resonance Imaging, vol. 26, no. 3, pp. 460–479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Maiseyeu, G. Mihai, T. Kampfrath et al., “Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis,” Journal of Lipid Research, vol. 50, no. 11, pp. 2157–2163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Chono, Y. Tauchi, and K. Morimoto, “Pharmacokinetic analysis of the uptake of liposomes by macrophages and foam cells in vitro and their distribution to atherosclerotic lesions in mice,” Drug Metabolism and Pharmacokinetics, vol. 21, no. 1, pp. 37–44, 2006. View at Publisher · View at Google Scholar
  103. S. P. Tam, J. B. Ancsin, R. Tan, and R. Kisilevsky, “Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/- mice,” Journal of Lipid Research, vol. 46, no. 10, pp. 2091–2101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. E. Kim, A. T. Tolhurst, Y. Q. Lu, X.-Y. Chen, M. Febbraio, and S. Cho, “CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury,” Journal of Neuroscience, vol. 28, no. 18, pp. 4661–4670, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. G. Ziegler, D. Harhausen, C. Schepers et al., “TLR2 has a detrimental role in mouse transient focal cerebral ischemia,” Biochemical and Biophysical Research Communications, vol. 359, no. 3, pp. 574–579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Tanaka, K. Kitagawa, S. Sugiura et al., “Infiltrating macrophages as in vivo targets for intravenous gene delivery in cerebral infarction,” Stroke, vol. 35, no. 8, pp. 1968–1973, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. K. Park, “Trojan monocytes for improved drug delivery to the brain,” Journal of Controlled Release, vol. 132, no. 2, p. 75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. Z. M. Saiyed, N. H. Gandhi, and M. P.N. Nair, “Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood-brain barrier,” International Journal of Nanomedicine, vol. 5, no. 1, pp. 157–166, 2010. View at Google Scholar
  109. E. Afergan, H. Epstein, R. Dahan et al., “Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes,” Journal of Controlled Release, vol. 132, no. 2, pp. 84–90, 2008. View at Publisher · View at Google Scholar · View at Scopus